• Phare
  • Validé par KD/KO

Anticorps Monoclonal anti-PRAME

PRAME Monoclonal Antibody for WB, IF/ICC, Indirect ELISA

Hôte / Isotype

Mouse / IgG2b

Réactivité testée

Humain, rat, souris

Applications

WB, IF/ICC, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

1E9G9

N° de cat : 68097-1-PBS

Synonymes

MAPE, OIP 4, OIP4, Opa interacting protein 4, PRAME



Informations sur le produit

68097-1-PBS cible PRAME dans les applications de WB, IF/ICC, Indirect ELISA et montre une réactivité avec des échantillons Humain, rat, souris

Réactivité Humain, rat, souris
Hôte / Isotype Mouse / IgG2b
Clonalité Monoclonal
Type Anticorps
Immunogène PRAME Protéine recombinante Ag1906
Nom complet preferentially expressed antigen in melanoma
Masse moléculaire calculée 509 aa, 58 kDa
Poids moléculaire observé50 kDa
Numéro d’acquisition GenBankBC014074
Symbole du gène PRAME
Identification du gène (NCBI) 23532
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

The PRAME (preferentially expressed antigen of melanoma) gene was previously shown to be overexpressed in ovarian/primary peritoneal serous carcinoma compared with malignant mesothelioma using gene expression arrays. It is considered a melanocyte differentiation antigen which is overexpressed in both solid and hematologic tumors. In normal tissue, a very low level of PRAME expression is found in normal testis, adrenals, ovary and endometrium. A high level of PRAME expression has been reported for several solid tumors, including ovarian cancer, breast cancer, lung cancer and melanomas, medulloblastoma, sarcomas, head and neck cancers, neuroblastoma, renal cancer, and Wilms'tumor. As a nuclear transcriptional repressor protein, PRAME binds to retinoic acid receptor a, thereby inhibiting retinoic acid induced differentiation, growth arrest, and apoptosis.

{{ptg:RelatedPrimaryAntibodies}}